Neurocrine Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.05.17	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q1 Earnings Report (RTTNews)
03.05.17	Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results (PR Newswire)
02.05.17	Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes (PR Newswire)
02.05.17	Four Seasons Hotels and Resorts Appoints Julia Hartz to Board of Directors (PR Newswire)
27.04.17	Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering (PR Newswire)
25.04.17	Neurocrine Announces Proposed Convertible Senior Notes Offering (PR Newswire)
24.04.17	How These Generic Drugs Stocks are Faring? -- Evoke Pharma, Neurocrine Biosciences, Lannett, and Catalent (PR Newswire)
24.04.17	Biotech Stocks Facing FDA Decision In May (RTTNews)
21.04.17	Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting (PR Newswire)
13.04.17	FusionStorm Renews Cisco Master Cloud Builder Specialization (PR Newswire)
13.04.17	Gainers & Losers Of Apr.12: ADPT, NBIX, NOVN, PLX, ALBO... (RTTNews)
12.04.17	FDA Approves 1st Drug For Tardive Dyskinesia, AGRX On Track, ITEK, AZRX On Watch (RTTNews)
12.04.17	FDA Oks Neurocrine's Ingrezza Capsules To Treat Adults With Tardive Dyskinesia (RTTNews)
11.04.17	Neurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (with multimedia) (PR Newswire)
11.04.17	Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD) (PR Newswire)
10.04.17	AKRX Confirms Acquisition Talks, CBIO Plunges, Be All Ears For GERN (RTTNews)
07.04.17	AbbVie: Data Shows Elagolix Reduces Menstrual Bleeding In Phase 2b Trial (RTTNews)
07.04.17	AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids (PR Newswire)
24.03.17	Biotech Stocks Facing FDA Decision In April (RTTNews)
21.03.17	Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia (PR Newswire)
17.03.17	How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Lannett, Rigel Pharma, and Catalent (PR Newswire)
14.02.17	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q4 Earnings Report (RTTNews)
14.02.17	Neurocrine Biosciences Reports Year-End 2016 Results and Provides Investor Update for 2017 (PR Newswire)
09.02.17	Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone (PR Newswire)
03.02.17	How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma (PR Newswire)
19.01.17	Hopeful of Reduced Regulation, Biotech Stocks Stay the Course with Advanced Drug Developments (PR Newswire)
18.01.17	ADHD Doesn't MEASURE Up, JAZZ Abuzz, NBIX Slips On Failed Study (RTTNews)
06.01.17	Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief Operating Officer (PR Newswire)
06.01.17	OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC (RTTNews)
06.01.17	Neurocrine Says FDA Cancels Psychopharmacologic Drugs Advisory Committee Meeting (RTTNews)
05.01.17	Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment of Tardive Dyskinesia (PR Newswire)
21.12.16	Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down (PR Newswire)
13.12.16	Healthcare Stocks on Investors' Radar -- Sophiris Bio, Catalyst Pharma, Neurocrine Biosciences, and Capital Senior Living (PR Newswire)
06.12.16	New Collaborations and Licensing Activities for Biotech/Pharma Industries Pick Up Pace Heading into 2017 (PR Newswire)
05.12.16	Neurocrine Biosciences Announces INGREZZA™ (valbenazine) Long-Term Data to be Presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology (PR Newswire)
30.11.16	Arrowhead Blunted, CERC Depressed, It's All Clear For NOVN, CPHR Leaves Nasdaq (RTTNews)
30.11.16	Arrowhead Blunted, CERC Depressed, It's All Clear For NOVN, CPHR Leaves Nasdaq (RTTNews)
30.11.16	Neurocrine Says FDA Advisory Committee Meeting On Feb. 16 To Review INGREZZA NDA (RTTNews)
30.11.16	Neurocrine Says FDA Advisory Committee Meeting On Feb. 16 To Review INGREZZA NDA (RTTNews)
29.11.16	Neurocrine Announces FDA Advisory Committee Meeting to Review INGREZZA™ (valbenazine) New Drug Application for the Treatment of Tardive Dyskinesia (PR Newswire)
21.11.16	Neurocrine Biosciences to Present at the 28th Annual Piper Jaffray Healthcare Conference (PR Newswire)
02.11.16	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q3 Earnings Report (RTTNews)
20.10.16	CERU Gains Big On Nanoparticle Deal, LLY Gets FDA Nod, BABY Makes Big Strides (RTTNews)
19.10.16	AbbVie Announces Positive Pivotal Phase 3 Data On Elagolix (RTTNews)
12.10.16	IPCI Continues To Move Up, NBIX To Face FDA In April, Good Tidings From NYMX (RTTNews)
11.10.16	Neurocrine: FDA Accepts For Priority Review INGREZZA NDA In Tardive Dyskinesia (RTTNews)
04.08.16	AXGN Making News, Milestone Events Lined Up For NBIX, Cesca Plays It Cool (RTTNews)
03.08.16	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q2 Earnings Report (RTTNews)
05.05.16	EARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q1 Earnings Report (RTTNews)
12.02.16	AEGR Lays Off 25% Staff, INCY Discontinues Ruxolitinib Trials, ZBH Gets FDA Nod (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
28.08.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter
28.08.24		Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag
28.08.24		Schwache Performance in New York: So steht der NASDAQ Composite aktuell
28.08.24		Schwacher Handel: NASDAQ Composite zum Handelsstart schwächer

30.10.24

Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach

30.10.24

Handel in New York: NASDAQ Composite verbucht Verluste

30.10.24

Gute Stimmung in New York: NASDAQ Composite mittags fester

30.10.24

Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone

28.08.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite präsentiert sich zum Handelsende leichter

28.08.24

Handel in New York: So performt der NASDAQ Composite am Mittwochnachmittag

28.08.24

Schwache Performance in New York: So steht der NASDAQ Composite aktuell

28.08.24

Schwacher Handel: NASDAQ Composite zum Handelsstart schwächer

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Neurocrine Biosciences Inc.

Aktien Top/Flop

Neurocrine Biosciences Peer Group Nachrichten

Meistgelesene Nachrichten